Gallium-68–Labeled Prostate-Specific Membrane Antigen–11 PET/CT of Prostate and Nonprostate Cancers
Saabry Osmany1,2, Sumbul Zaheer3,4, Twyla B. Bartel5, Mickaila Johnston6 ... Show all
Share Share
+ Affiliations:
Citation: American Journal of Roentgenology: 1-14. 10.2214/AJR.19.21084
AbstractFull TextReferencesPDFPDF PlusAdd to FavoritesPermissionsDownload Citation
ABSTRACT :
OBJECTIVE. The purpose of this study is to provide a concise summary of the current experience with 68Ga-labeled prostate-specific membrane antigen (PSMA)–11 imaging of prostate and nonprostate malignancies and benign conditions.
CONCLUSION. PSMA is overexpressed in prostate cancer and in the neovasculature of many other malignancies. The relevance of PSMA as a biologic target, coupled with advances in the design, synthesis, and evaluation of PSMA-based radionuclides for imaging and therapy, is anticipated to play a major role in patient care.
Keywords: 68Ga-PSMA, benign PSMA uptake, nonprostate malignancy, PET, prostate cancer
Supported by grants R21-EB017568 and P30-CA014089 from the National Institutes of Health to H. Jadvar.
References
Previous section
1. Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA theranostics: current status and future directions. Mol Imaging 2018; 17:1536012118776068 [Crossref] [Google Scholar]
2. Kirchner J, Schaarschmidt BM, Sawicki LM, et al. Evaluation of practical interpretation hurdles in 68 Ga-PSMA PET/CT in 55 patients: physiological tracer distribution and incidental tracer up-take. Clin Nucl Med 2017; 42:e322–e327 [Crossref] [Medline] [Google Scholar]
3. Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. RadioGraphics 2018; 38:200–217 [Crossref] [Medline] [Google Scholar]
4. Bhardwaj H, Stephens M, Bhatt M, Thomas PA. Prostate-specific membrane antigen PET/CT findings for hepatic hemangioma. Clin Nucl Med 2016; 41:968–969 [Crossref] [Medline] [Google Scholar]
5. Rischpler C, Beck TI, Okamoto S, et al. 68 Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med 2018; 59:1406–1411 [Crossref] [Medline] [Google Scholar]
6. Beheshti M, Rezaee A, Langsteger W. 68 Ga-PSMA-HBED uptake on cervicothoracic (stel-late) ganglia, a common pitfall on PET/CT. Clin Nucl Med 2017; 42:195–196 [Crossref] [Medline] [Google Scholar]
7. Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 2018; 59:469–478 [Crossref] [Medline] [Google Scholar]
8. Kasoha M, Unger C, Solomayer E-F, et al. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis 2017; 34:479–490 [Crossref] [Medline] [Google Scholar]
9. Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med 2018; 215:159–175 [Crossref] [Medline] [Google Scholar]
10. Jadvar H, Ballas LK. PSMA PET: transformational change in prostate cancer management? J Nucl Med 2018; 59:228–229 [Crossref] [Medline] [Google Scholar]
11. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45:471–495 [Crossref] [Medline] [Google Scholar]
12. Woythal N, Arsenic R, Kempkensteffen C, et al. Immunohistochemical validation of PSMA expression measured by 68 Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med 2018; 59:238–243 [Crossref] [Medline] [Google Scholar]
13. Uprimny C, Kroiss AS, Decristoforo C, et al. 68 Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44:941–949 [Crossref] [Medline] [Google Scholar]
14. Kesch C, Radtke J-P, Wintsche A, et al. Correlation between genomic index lesions and mpMRI and 68 Ga-PSMA-PET/CT imaging features in primary prostate cancer. Sci Rep 2018; 8:16708 [Crossref] [Medline] [Google Scholar]
15. Berger I, Annabattula C, Lewis J, et al. 68 Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis 2018; 21:204–211 [Crossref] [Medline] [Google Scholar]
16. Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF. 68 Ga-PSMA-11 PET/CT in newly diagnosed prostate adenocarcinoma. Clin Nucl Med 2018; 43:e422–e427 [Medline] [Google Scholar]
17. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Meta-analysis of 68 Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med 2018 Dec 7 [Epub ahead of print] [Google Scholar]
18. Thomas L, Kantz S, Hung A, et al. 68 Ga-PSMAPET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost. Eur J Nucl Med Mol Imaging 2018; 45:1170–1178 [Crossref] [Medline] [Google Scholar]
19. Calais J, Kishan AU, Cao M, et al. Potential impact of 68 Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer. J Nucl Med 2018; 59:1714–1721 [Crossref] [Medline] [Google Scholar]
20. Schiller K, Devecka M, Maurer T, et al. Impact of 68 Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology: a patterns of failure analysis in patients with primary diagnosis of prostate cancer. Radiat Oncol 2018; 13:36 [Crossref] [Medline] [Google Scholar]
21. Roach PJ, Francis R, Emmett L, et al. The impact of 68 Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 2018; 59:82–88 [Crossref] [Medline] [Google Scholar]
22. Afaq A, Alahmed S, Chen S-H, et al. Impact of 68 Ga-prostate-specific membrane antigen PET/CT on prostate cancer management. J Nucl Med 2018; 59:89–92 [Crossref] [Medline] [Google Scholar]
23. Hope TA, Aggarwal R, Chee B, et al. Impact of 68 Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med 2017; 58:1956–1961 [Crossref] [Medline] [Google Scholar]
24. Einspieler I, Rauscher I, Düwel C, et al. Detection efficacy of hybrid 68 Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria. J Nucl Med 2017; 58:1081–1087 [Crossref] [Medline] [Google Scholar]
25. Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with 68 Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med 2017; 58:750–755 [Crossref] [Medline] [Google Scholar]
26. Farolfi A, Ceci F, Castellucci P, et al. 68 Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml: efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging 2019; 46:11–19 [Crossref] [Medline] [Google Scholar]
27. Ceci F, Castellucci P, Graziani T, et al. 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging 2019; 46:31–39 [Crossref] [Medline] [Google Scholar]
28. Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43:397–403 [Crossref] [Medline] [Google Scholar]
29. Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68 Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44:1258–1268 [Crossref] [Medline] [Google Scholar]
30. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68 Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016; 70:926–937 [Crossref] [Medline] [Google Scholar]
31. Calais J, Czernin J, Cao M, et al. 68 Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med 2018; 59:230–237 [Crossref] [Medline] [Google Scholar]
32. Emmett L, van Leeuwen PJ, Nandurkar R, et al. Treatment outcomes from 68 Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET. J Nucl Med 2017; 58:1972–1976 [Crossref] [Medline] [Google Scholar]
33. Han S, Woo S, Kim YJ, Suh CH. Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2018; 74:179–190 [Crossref] [Medline] [Google Scholar]
34. Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68 Ga-PSMA-positron emission tomography/computerized tomography. Prostate 2015; 75:1934–1940 [Crossref] [Medline] [Google Scholar]
35. Soldatov A, von Klot CAJ, Walacides D, et al. Patterns of progression after 68 Ga-PSMA-ligand PET/CT-guided radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 2019; 103:95–104 [Crossref] [Medline] [Google Scholar]
36. Lengana T, Lawal IO, Boshomane TG, et al. 68 Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer 2018; 16:392–401 [Crossref] [Medline] [Google Scholar]
37. Zacho HD, Nielsen JB, Afshar-Oromieh A, et al. Prospective comparison of 68 Ga-PSMA PET/CT, 18 F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45:1884–1897 [Crossref] [Medline] [Google Scholar]
38. Uprimny C, Svirydenka A, Fritz J, et al. Comparison of [68 Ga]Ga-PSMA-11 PET/CT with [18 F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Eur J Nucl Med Mol Imaging 2018; 45:1873–1883 [Crossref] [Medline] [Google Scholar]
39. Hope TA, Truillet C, Ehman EC, et al. 68 Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med 2017; 58:81–84 [Crossref] [Medline] [Google Scholar]
40. Afshar-Oromieh A, Debus N, Uhrig M, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45:2045–2054 [Crossref] [Medline] [Google Scholar]
41. Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA. Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study. Nucl Med Mol Imaging 2018; 52:420–429 [Crossref] [Medline] [Google Scholar]
42. Seitz AK, Rauscher I, Haller B, et al. Preliminary results on response assessment using 68 Ga-HBED-CC-PSMA PET/CT in patients with meta-static prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging 2018; 45:602–612 [Crossref] [Medline] [Google Scholar]
43. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177 Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017; 58:85–90 [Crossref] [Medline] [Google Scholar]
44. Hofman MS, Violet J, Hicks RJ, et al. [177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19:825–833 [Crossref] [Medline] [Google Scholar]
45. Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016; 43:795–796 [Crossref] [Medline] [Google Scholar]
46. Osman MM, Iravani A, Hicks RJ, Hofman MS. Detection of synchronous primary malignancies with 68 Ga-labeled prostate-specific membrane antigen PET/CT in patients with prostate cancer: frequency in 764 patients. J Nucl Med 2017; 58:1938–1942 [Crossref] [Medline] [Google Scholar]
47. Jochumsen MR, Gormsen LC, Nielsen GL. 68 Ga-PSMA avid primary adenocarcinoma of the lung with complementary low 18 F-FDG uptake. Clin Nucl Med 2018; 43:117–119 [Crossref] [Medline] [Google Scholar]
48. Huang HL, Zhen Loh TJ, Hoe Chow PK. A case of well-differentiated hepatocellular carcinoma identified on gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography. World J Nucl Med 2018; 17:102–105 [Medline] [Google Scholar]
49. Sasikumar A, Joy A, Pillai MRA, et al. Diagnostic value of 68 Ga PSMA-11 PET/CT imaging of brain tumors: preliminary analysis. Clin Nucl Med 2017; 42:e41–e48 [Crossref] [Medline] [Google Scholar]
50. Sasikumar A, Kashyap R, Joy A, et al. Utility of 68 Ga-PSMA-11 PET/CT in imaging of glioma: a pilot study. Clin Nucl Med 2018; 43:e304–e309 [Crossref] [Medline] [Google Scholar]
51. Arora S, Damle NA, Aggarwal S, et al. Prostate-specific membrane antigen expression in adreno-cortical carcinoma on 68 Ga-prostate-specific membrane antigen PET/CT. Clin Nucl Med 2018; 43:449–451. [Medline] [Google Scholar]
52. Stoykow C, Huber-Schumacher S, Almanasreh N, Jilg C, Ruf J. Strong PSMA radioligand up-take by rectal carcinoma: who put the “S” in PSMA? Clin Nucl Med 2017; 42:225–226 [Crossref] [Medline] [Google Scholar]
53. Hangaard L, Jochumsen MR, Vendelbo MH, Bouchelouche K. Metastases from colorectal cancer avid on 68 Ga-PSMA PET/CT. Clin Nucl Med 2017; 42:532–533 [Crossref] [Medline] [Google Scholar]
54. Huang Y-TT, Fong W, Thomas P. Rectal carcinoma on 68 Ga-PSMA PET/CT. Clin Nucl Med 2016; 41:e167–e168 [Crossref] [Medline] [Google Scholar]
55. Noto B, Weckesser M, Buerke B, Pixberg M, Avramovic N. Gastrointestinal stromal tumor showing intense tracer uptake on PSMA PET/CT. Clin Nucl Med 2017; 42:200–202 [Crossref] [Medline] [Google Scholar]
56. Laurens ST, Witjes F, Janssen M, Flucke U, Gottardt M. 68 Ga-prostate-specific membrane antigen uptake in gastrointestinal stromal tumor. Clin Nucl Med 2018; 43:60–61 [Crossref] [Medline] [Google Scholar]
57. Sasikumar A, Joy A, Pillai M, S B, Sr S. 68Ga-PSMA uptake in an incidentally detected gastrointestinal stromal tumor in a case of suspected carcinoma prostate. Clin Nucl Med 2017; 42:e447–e448 [Crossref] [Medline] [Google Scholar]
58. Kesler M, Levine C, Hershkovitz D, et al. 68 Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med 2018 Jul 12 [Epub ahead of print] [Medline] [Google Scholar]
59. Demirkol MO, Kiremit MC, Acar O, Sag AA, Kapran Y. False-positive pancreatic uptake detected on 68 Ga-PSMA PET/CT: a priority changing incidental finding while assessing the need for a prostate biopsy. Clin Nucl Med 2017; 42:e475–e477 [Crossref] [Medline] [Google Scholar]
60. Parihar AS, Vadi SK, Mittal BR, Kumar R, Bal A, Singh SK. 68 Ga-PSMA-HBED-CC-avid synchronous urinary bladder paraganglioma in a patient with metastatic prostate carcinoma. Clin Nucl Med 2018; 43:e329–e330 [Crossref] [Medline] [Google Scholar]
61. Parida GK, Tripathy S, Datta Gupta S, et al. Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18 F-FDG PET/CT and 68 Ga-DOTANOC PET/CT over 68 Ga-PSMA PET/CT. Clin Nucl Med 2018; 43:248–249 [Medline] [Google Scholar]
62. Usmani S, Ahmed N, Marafi F, Rasheed R, Amanguno HG, Al Kandari F. Molecular imaging in neuroendocrine differentiation of prostate cancer: 68 Ga-PSMA versus 68 Ga-DOTA NOC PET-CT. Clin Nucl Med 2017; 42:410–413 [Crossref] [Medline] [Google Scholar]
63. Chen S, Cheung SK, Wong K-N, Wong KK, Ho C-L. 68 Ga-DOTATOC and 68 Ga-PSMA PET/CT unmasked a case of prostate cancer with neuroendocrine differentiation. Clin Nucl Med 2016; 41:959–960 [Crossref] [Medline] [Google Scholar]
64. Singh D, Kumar R, Mittal BR, Singh H, Bhattacharya A. 68 Ga-labeled prostate-specific membrane antigen uptake in pheochromocytoma: an incidental finding in PET/CT scan. Clin Nucl Med 2018; 43:688–690 [Crossref] [Medline] [Google Scholar]
65. Evangelista L, Basso U, Maruzzo M, Novara G. The role of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for the evaluation of renal cancer. Eur Urol Focus 2018 Aug 14 [Epub ahead of print] [Crossref] [Medline] [Google Scholar]
66. Rhee H, Ng KL, Tse BW-C, et al. Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology 2016; 48:613–616 [Crossref] [Medline] [Google Scholar]
67. Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a 68 Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging 2017; 44:102–107 [Crossref] [Medline] [Google Scholar]
68. Demirci E, Ocak M, Kabasakal L, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2014; 41:1461–1462 [Crossref] [Medline] [Google Scholar]
69. Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68 Ga prostate specific membrane antigen positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol 2017; 61:372–378 [Crossref] [Medline] [Google Scholar]
70. Einspieler I, Tauber R, Maurer T, Schwaiger M, Eiber M. 68 Ga prostate-specific membrane antigen uptake in renal cell cancer lymph node metastases. Clin Nucl Med 2016; 41:e261–e262 [Crossref] [Medline] [Google Scholar]
71. Gupta M, Choudhury PS, Gupta G, Gandhi J. Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy. Indian J Nucl Med 2016; 31:222–224 [Crossref] [Medline] [Google Scholar]
72. Merrild EH, Baerentzen S, Bouchelouche K, Buus S. Vertebral myeloma mimicking prostatic carcinoma metastasis in 68 Ga-PSMA PET/CT. Clin Nucl Med 2017; 42:790–792 [Crossref] [Medline] [Google Scholar]
73. Rauscher I, Maurer T, Steiger K, Schwaiger M, Eiber M. Image of the month: multifocal 68 Ga prostate-specific membrane antigen ligand up-take in the skeleton in a man with both prostate cancer and multiple myeloma. Clin Nucl Med 2017; 42:547–548 [Crossref] [Medline] [Google Scholar]
74. Sasikumar A, Joy A, Pillai MRA, Nanabala R, Thomas B. 68 Ga-PSMA PET/CT imaging in multiple myeloma. Clin Nucl Med 2017; 42:e126–e127 [Crossref] [Medline] [Google Scholar]
75. Sasikumar A, Joy A, Pillai MRA, Alex TM, Narayanan G. 68 Ga-PSMA PET/CT in osteosarcoma in fibrous dysplasia. Clin Nucl Med 2017; 42:446–447 [Crossref] [Medline] [Google Scholar]
76. De Coster L, Sciot R, Everaerts W, et al. Fibrous dysplasia mimicking bone metastasis on 68 GA PSMA PET/MRI. Eur J Nucl Med Mol Imaging 2017; 44:1607–1608 [Crossref] [Medline] [Google Scholar]
77. Sakthivel P, Prashanth A, Thakar A, Kumar R, Kumar R. Juvenile nasal angiofibroma on 68 Ga-PSMA PET/CT: opening new frontiers. Clin Nucl Med 2019; 44:e118–e119 [Crossref] [Medline] [Google Scholar]
78. Krishnaraju VS, Basher RK, Singh H, Singh SK, Bal A, Mittal BR. Incidental detection of type B2 thymoma on 68 Ga-labeled prostate-specific membrane antigen PET/CT imaging. Clin Nucl Med 2018; 43:356–358 [Medline] [Google Scholar]
79. Farolfi A, Ceci F, Graziani T, et al. Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in a patient with recurrent prostate cancer. Clin Genitourin Cancer 2018; 16:e497–e499 [Crossref] [Medline] [Google Scholar]
80. Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental detection of head and neck squamous cell carcinoma on 68 Ga-PSMA-11 PET/CT. Clin Nucl Med 2017; 42:e218–e220 [Crossref] [Medline] [Google Scholar]
81. Verma P, Malhotra G, Agrawal R, Sonavane S, Meshram V, Asopa RV. Evidence of prostate-specific membrane antigen expression in meta-static differentiated thyroid cancer using 68 Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med 2018; 43:e265–e268 [Crossref] [Medline] [Google Scholar]
82. Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer? Clin Nucl Med 2016; 41:e263–e265 [Crossref] [Medline] [Google Scholar]
83. Sasikumar A, Joy A, Pillai MRA, Oommen KE, Jayakumar R. Rare case of intratracheal metastasis detected on 68 Ga-prostate-specific membrane antigen PET/CT scan in a case of thyroglobulin elevated negative iodine scan syndrome. Clin Nucl Med 2018; 43:282–283 [Medline] [Google Scholar]
84. Sager S, Vatankulu B, Uslu L, Sönmezoglu K. Incidental detection of follicular thyroid carcinoma in 68 Ga-PSMA PET/CT imaging. J Nucl Med Technol 2016; 44:199–200 [Crossref] [Medline] [Google Scholar]
85. Damle NA, Bal C, Singh TP, et al. Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers. Eur J Nucl Med Mol Imaging 2018; 45:667–668 [Crossref] [Medline] [Google Scholar]
86. Jena A, Zaidi S, Kashyap V, Jha A, Taneja S. PSMA expression in multinodular thyroid neoplasm on simultaneous Ga-68-PSMA PET/MRI. Indian J Nucl Med 2017; 32:159–161 [Crossref] [Medline] [Google Scholar]
87. Derlin T, Kreipe H-H, Schumacher U, Soudah B. PSMA expression in tumor neovasculature endothelial cells of follicular thyroid adenoma as identified by molecular imaging using 68 Ga-PSMA ligand PET/CT. Clin Nucl Med 2017; 42:e173–e174 [Crossref] [Medline] [Google Scholar]
88. Damle NA, Tripathi M, Chakraborty PS, et al. Unusual uptake of prostate specific tracer 68 Ga-PSMA-HBED-CC in a benign thyroid nodule. Nucl Med Mol Imaging 2016; 50:344–347 [Crossref] [Medline] [Google Scholar]
89. Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E. Follicular thyroid adenoma showing avid uptake on 68 Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016; 41:331–332 [Crossref] [Medline] [Google Scholar]
90. Patro KC, Palla M, Kashyap R. Unusual case of metastatic intracranial hemangiopericytoma and emphasis on role of 68 Ga-PSMA PET in imaging. Clin Nucl Med 2018; 43:e331–e333 [Crossref] [Medline] [Google Scholar]
91. Malik D, Mittal BR, Kumar R, Singh H, Bhattacharya A, Singh SK. Incidental detection of tracer avidity in liposarcoma on 68 Ga-labeled prostate-specific membrane antigen PET/CT. Clin Nucl Med 2018; 43:e334–e335 [Crossref] [Medline] [Google Scholar]
92. Snow HA, Hofman MS, Mitchell CA, Gyorki DE, Smith MJF. Incidental metastatic melanoma identified on 68 Ga-prostate-specific membrane antigen PET/CT for metastatic prostate cancer. Clin Nucl Med 2018; 43:509–511 [Crossref] [Medline] [Google Scholar]
93. Anconina R, Hod N, Levin D, Ezroh Kazap D, Lantsberg S. Incidental detection of metastatic malignant melanoma on 68 Ga-prostate-specific membrane antigen PET/CT imaging: correlative imaging with FDG PET/CT and review of the literature. Clin Nucl Med 2018; 43:204–206 [Crossref] [Medline] [Google Scholar]
94. Vamadevan S, Le K, Bui C, Mansberg R. Prostate-specific membrane antigen uptake in small cleaved B-cell follicular non-Hodgkin lymphoma. Clin Nucl Med 2016; 41:980–981 [Crossref] [Medline] [Google Scholar]
95. Kanthan GL, Coyle L, Kneebone A, Schembri GP, Hsiao E. Follicular lymphoma showing avid uptake on 68 Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016; 41:500–501 [Crossref] [Medline] [Google Scholar]
96. Sathekge M, Lengana T, Modiselle M, et al. 68 Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging 2017; 44:689–694 [Crossref] [Medline] [Google Scholar]
97. Sathekge M, Modiselle M, Vorster M, et al. 68 Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging 2015; 42:1482–1483 [Crossref] [Medline] [Google Scholar]
98. Chia JY, Loi HY, Khor LK, Joe Lee KC, Seow YH. Primary lung adenocarcinoma with 68 gallium prostate-specific membrane antigen-PET/CT scan avidity in a patient on surveillance after prostatectomy. Clin Genitourin Cancer 2018; 16:e525–e527 [Crossref] [Medline] [Google Scholar]
99. Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68 Ga prostate-specific membrane antigen activity in metastatic non-small cell lung cancer. Clin Nucl Med 2016; 41:414–416 [Crossref] [Medline] [Google Scholar]
100. Backhaus P, Noto B, Avramovic N, et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging 2018; 45:860–877 [Crossref] [Medline] [Google Scholar]
101. Jochumsen MR, Bouchelouche K. Intense 68 Ga-PSMA uptake in diverticulum of the sigmoid colon. Clin Nucl Med 2018; 43:110–111 [Crossref] [Medline] [Google Scholar]
102. Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK. 68 Ga-labeled PSMA uptake in nonprostatic malignancies: has the time come to remove “PS” From PSMA? Clin Nucl Med 2018; 43:529–532 [Crossref] [Medline] [Google Scholar]
103. Pfob CH, Karimov I, Jesinghaus M, et al. Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma. Eur J Nucl Med Mol Imaging 2018 Dec 19 [Epub ahead of print] [Google Scholar]
104. Lütje S, Gomez B, Cohnen J, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68 Ga-HBED-CC-PSMA PET/CT. Clin Nucl Med 2017; 42:20–25 [Crossref] [Medline] [Google Scholar]
105. Dekker I, van der Leest M, van Rijk MC, Gerritsen WR, Arens AIJ. 68 Ga-PSMA uptake in angiolipoma. Clin Nucl Med 2018; 43:757–758 [Medline] [Google Scholar]
106. Bilgin R, Ergül N, Çermik TF. Incidental meningioma mimicking metastasis of prostate adeno-carcinoma in 68 Ga-labeled PSMA ligand PET/CT. Clin Nucl Med 2016; 41:956–958 [Crossref] [Medline] [Google Scholar]
107. Vadi SK, Kumar R, Singh H, Singh SK, Mittal BR. 68 Ga-prostate-specific membrane antigen expression in neurocysticercosis lesions in a patient with prostate carcinoma. Clin Nucl Med 2018; 43:e122–e124 [Medline] [Google Scholar]
108. Stephens M, Kim DI, Shepherd B, Gustafson S, Thomas P. Intense uptake in amyloidosis of the seminal vesicles on 68 Ga-PSMA PET mimicking locally advanced prostate cancer. Clin Nucl Med 2017; 42:147–148 [Crossref] [Medline] [Google Scholar]
109. Pyka T, Weirich G, Einspieler I, et al. 68 Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med 2016; 57:367–371 [Crossref] [Medline] [Google Scholar]
110. Daglioz Gorur G, Hekimsoy T, Isgoren S. Re: false positive uptake in bilateral gynecomastia on 68 Ga-PSMA PET/CT scan. Clin Nucl Med 2018; 43:785 [Medline] [Google Scholar]
111. Pedersen MA, Bouchelouche K, Vendelbo MH. 68 Ga-PSMA uptake in middle lobe syndrome. Clin Nucl Med 2018; 43:e376–e377 [Medline] [Google Scholar]
112. Huang HL, Dharmawan AR, Tan CJ, Thang SP. A rare case of thymoma first detected on gallium-68 PSMA PET/CT. Eur J Nucl Med Mol Imaging 2017; 44:2148–2149 [Crossref] [Medline] [Google Scholar]
113. Strele-Trieb P, Dunzinger A, Sonnberger M, Wolfsgruber J, Pichler R. Uptake of 68 Ga-prostate-specific membrane antigen PET in adrenal gland: a potential pitfall. Clin Nucl Med 2018; 43:50–51 [Crossref] [Medline] [Google Scholar]
114. Law WP, Fiumara F, Fong W, Miles KA. Gallium-68 PSMA uptake in adrenal adenoma. J Med Imaging Radiat Oncol 2016; 60:514–517 [Crossref] [Medline] [Google Scholar]
115. Jochumsen MR, Dias AH, Bouchelouche K. Benign traumatic rib fracture: a potential pitfall on 68 Ga-prostate-specific membrane antigen PET/CT for prostate cancer. Clin Nucl Med 2018; 43:38–40 [Crossref] [Medline] [Google Scholar]
116. Vamadevan S, Le K, Bui C, Mansberg R. Incidental PSMA uptake in an undisplaced fracture of a vertebral body. Clin Nucl Med 2017; 42:465–466 [Crossref] [Medline] [Google Scholar]
117. Hoberück S, Michler E, Kaiser D, Röhnert A, Zöphel K, Kotzerke J. Prostate-specific membrane antigen expression in distal radius fracture. Clin Nucl Med 2018; 43:611–613 [Crossref] [Medline] [Google Scholar]
118. Gykiere P, Goethals L, Everaert H. Healing sacral fracture masquerading as metastatic bone disease on a 68 Ga-PSMA PET/CT. Clin Nucl Med 2016; 41:e346–e347 [Crossref] [Medline] [Google Scholar]
119. Castello A, Lopci E. Incidental identification of osteoid osteoma by 68 Ga-PSMA PET/CT. Eur J Nucl Med Mol Imaging 2018; 45:509–510 [Crossref] [Medline] [Google Scholar]
120. Shetty D, Patel D, Le K, Bui C, Mansberg R. Pitfalls in gallium-68 PSMA PET/CT interpretation: a pictorial review. Tomography 2018; 4:182–193 [Crossref] [Medline] [Google Scholar]
121. Froehner M, Toma M, Zöphel K, Novotny V, Laniado M, Wirth MP. PSMA-PET/CT-positive Paget disease in a patient with newly diagnosed prostate cancer: imaging and bone biopsy findings. Case Rep Urol 2017; 2017:1654231 [Medline] [Google Scholar]
122. Bourgeois S, Gykiere P, Goethals L, Everaert H, De Geeter FW. Aspecific uptake of 68GA-PSMA in Paget disease of the bone. Clin Nucl Med 2016; 41:877–878 [Crossref] [Medline] [Google Scholar]
123. Artigas C, Alexiou J, Garcia C, et al. Paget bone disease demonstrated on (68) Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging 2016; 43:195–196 [Crossref] [Medline] [Google Scholar]
124. Sahoo MK, Ahlawat K, Yadav R, Gajendra S. Schmorl's node: confusion still persists in (68) Ga-prostate-specific membrane antigen ligand PET/CT. Clin Nucl Med 2018; 43:679–681 [Crossref] [Medline] [Google Scholar]
125. Probst S, Bladou F, Abikhzer G. Extraosseous extension of aggressive vertebral hemangioma as a potential pitfall on 68 Ga-PSMA PET/CT. Clin Nucl Med 2017; 42:624–625 [Medline] [Google Scholar]
126. Zacho HD, Nielsen JB, Dettmann K, Hjulskov SH, Petersen LJ. 68 Ga-PSMA PET/CT uptake in intramuscular myxoma imitates prostate cancer metastasis. Clin Nucl Med 2017; 42:487–488 [Crossref] [Medline] [Google Scholar]
127. Oh G, Miles K. Subacute cerebellar infarction with uptake on 68 Ga–prostate-specific membrane antigen PET/CT. Clin Nucl Med 2018; 43:134–135 [Crossref] [Medline] [Google Scholar]
128. Chan M, Hsiao E. Subacute cortical infarct showing uptake on 68 Ga-PSMA PET/CT. Clin Nucl Med 2017; 42:110–111 [Crossref] [Medline] [Google Scholar]
129. Dias AH, Bouchelouche K. Prostate-specific membrane antigen PET/CT incidental finding of a schwannoma. Clin Nucl Med 2018; 43:267–268 [Medline] [Google Scholar]
130. Rischpler C, Maurer T, Schwaiger M, Eiber M. Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging 2016; 43:193–194 [Crossref] [Medline] [Google Scholar]
131. Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Im-aging 2017; 44:2117–2136 [Crossref] [Medline] [Google Scholar]
132. Dias AH, Holm Vendelbo M, Bouchelouche K. Prostate-specific membrane antigen PET/CT: up-take in lymph nodes with active sarcoidosis. Clin Nucl Med 2017; 42:e175–e176 [Crossref] [Medline] [Google Scholar]
133. Hermann RM, Djannatian M, Czech N, Nitsche M. Prostate-specific membrane antigen PET/CT: false-positive results due to sarcoidosis? Case Rep Oncol 2016; 9:457–463 [Crossref] [Medline] [Google Scholar]
134. Kobe C, Maintz D, Fischer T, Drzezga A, Chang D-H. Prostate-specific membrane antigen PET/CT in splenic sarcoidosis. Clin Nucl Med 2015; 40:897–898 [Crossref] [Medline] [Google Scholar]
135. Elri T, Aras M, Salihoglu YS, Erdemir RU, Cabuk M. A potential pitfall in the use of 68 Ga-PSMA PET/CT: anthracosis. Rev Esp Med Nucl Imagen Mol 2017; 36:65–66 [Medline] [Google Scholar]
136. McGuiness M, Sounness B. 68 Ga-PSMA-ligand PET/CT uptake in anthracosilicosis. Clin Nucl Med 2017; 42:e431–e432 [Crossref] [Medline] [Google Scholar]
137. Klein Nulent TJ, van Es RJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma: a preliminary analysis. Eur J Nucl Med Mol Imaging 2017; 44:1614–1621 [Crossref] [Medline] [Google Scholar]
Address correspondence to S. Osmany (saabry@yahoo.com).
Read More: https://www.ajronline.org/doi/abs/10.2214/AJR.19.21084
Saabry Osmany1,2, Sumbul Zaheer3,4, Twyla B. Bartel5, Mickaila Johnston6 ... Show all
Share Share
+ Affiliations:
Citation: American Journal of Roentgenology: 1-14. 10.2214/AJR.19.21084
AbstractFull TextReferencesPDFPDF PlusAdd to FavoritesPermissionsDownload Citation
ABSTRACT :
OBJECTIVE. The purpose of this study is to provide a concise summary of the current experience with 68Ga-labeled prostate-specific membrane antigen (PSMA)–11 imaging of prostate and nonprostate malignancies and benign conditions.
CONCLUSION. PSMA is overexpressed in prostate cancer and in the neovasculature of many other malignancies. The relevance of PSMA as a biologic target, coupled with advances in the design, synthesis, and evaluation of PSMA-based radionuclides for imaging and therapy, is anticipated to play a major role in patient care.
Keywords: 68Ga-PSMA, benign PSMA uptake, nonprostate malignancy, PET, prostate cancer
Supported by grants R21-EB017568 and P30-CA014089 from the National Institutes of Health to H. Jadvar.
References
Previous section
1. Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA theranostics: current status and future directions. Mol Imaging 2018; 17:1536012118776068 [Crossref] [Google Scholar]
2. Kirchner J, Schaarschmidt BM, Sawicki LM, et al. Evaluation of practical interpretation hurdles in 68 Ga-PSMA PET/CT in 55 patients: physiological tracer distribution and incidental tracer up-take. Clin Nucl Med 2017; 42:e322–e327 [Crossref] [Medline] [Google Scholar]
3. Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. RadioGraphics 2018; 38:200–217 [Crossref] [Medline] [Google Scholar]
4. Bhardwaj H, Stephens M, Bhatt M, Thomas PA. Prostate-specific membrane antigen PET/CT findings for hepatic hemangioma. Clin Nucl Med 2016; 41:968–969 [Crossref] [Medline] [Google Scholar]
5. Rischpler C, Beck TI, Okamoto S, et al. 68 Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med 2018; 59:1406–1411 [Crossref] [Medline] [Google Scholar]
6. Beheshti M, Rezaee A, Langsteger W. 68 Ga-PSMA-HBED uptake on cervicothoracic (stel-late) ganglia, a common pitfall on PET/CT. Clin Nucl Med 2017; 42:195–196 [Crossref] [Medline] [Google Scholar]
7. Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 2018; 59:469–478 [Crossref] [Medline] [Google Scholar]
8. Kasoha M, Unger C, Solomayer E-F, et al. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis 2017; 34:479–490 [Crossref] [Medline] [Google Scholar]
9. Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med 2018; 215:159–175 [Crossref] [Medline] [Google Scholar]
10. Jadvar H, Ballas LK. PSMA PET: transformational change in prostate cancer management? J Nucl Med 2018; 59:228–229 [Crossref] [Medline] [Google Scholar]
11. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45:471–495 [Crossref] [Medline] [Google Scholar]
12. Woythal N, Arsenic R, Kempkensteffen C, et al. Immunohistochemical validation of PSMA expression measured by 68 Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med 2018; 59:238–243 [Crossref] [Medline] [Google Scholar]
13. Uprimny C, Kroiss AS, Decristoforo C, et al. 68 Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44:941–949 [Crossref] [Medline] [Google Scholar]
14. Kesch C, Radtke J-P, Wintsche A, et al. Correlation between genomic index lesions and mpMRI and 68 Ga-PSMA-PET/CT imaging features in primary prostate cancer. Sci Rep 2018; 8:16708 [Crossref] [Medline] [Google Scholar]
15. Berger I, Annabattula C, Lewis J, et al. 68 Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis 2018; 21:204–211 [Crossref] [Medline] [Google Scholar]
16. Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF. 68 Ga-PSMA-11 PET/CT in newly diagnosed prostate adenocarcinoma. Clin Nucl Med 2018; 43:e422–e427 [Medline] [Google Scholar]
17. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Meta-analysis of 68 Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med 2018 Dec 7 [Epub ahead of print] [Google Scholar]
18. Thomas L, Kantz S, Hung A, et al. 68 Ga-PSMAPET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost. Eur J Nucl Med Mol Imaging 2018; 45:1170–1178 [Crossref] [Medline] [Google Scholar]
19. Calais J, Kishan AU, Cao M, et al. Potential impact of 68 Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer. J Nucl Med 2018; 59:1714–1721 [Crossref] [Medline] [Google Scholar]
20. Schiller K, Devecka M, Maurer T, et al. Impact of 68 Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology: a patterns of failure analysis in patients with primary diagnosis of prostate cancer. Radiat Oncol 2018; 13:36 [Crossref] [Medline] [Google Scholar]
21. Roach PJ, Francis R, Emmett L, et al. The impact of 68 Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 2018; 59:82–88 [Crossref] [Medline] [Google Scholar]
22. Afaq A, Alahmed S, Chen S-H, et al. Impact of 68 Ga-prostate-specific membrane antigen PET/CT on prostate cancer management. J Nucl Med 2018; 59:89–92 [Crossref] [Medline] [Google Scholar]
23. Hope TA, Aggarwal R, Chee B, et al. Impact of 68 Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med 2017; 58:1956–1961 [Crossref] [Medline] [Google Scholar]
24. Einspieler I, Rauscher I, Düwel C, et al. Detection efficacy of hybrid 68 Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria. J Nucl Med 2017; 58:1081–1087 [Crossref] [Medline] [Google Scholar]
25. Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with 68 Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med 2017; 58:750–755 [Crossref] [Medline] [Google Scholar]
26. Farolfi A, Ceci F, Castellucci P, et al. 68 Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml: efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging 2019; 46:11–19 [Crossref] [Medline] [Google Scholar]
27. Ceci F, Castellucci P, Graziani T, et al. 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging 2019; 46:31–39 [Crossref] [Medline] [Google Scholar]
28. Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43:397–403 [Crossref] [Medline] [Google Scholar]
29. Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68 Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44:1258–1268 [Crossref] [Medline] [Google Scholar]
30. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68 Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016; 70:926–937 [Crossref] [Medline] [Google Scholar]
31. Calais J, Czernin J, Cao M, et al. 68 Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med 2018; 59:230–237 [Crossref] [Medline] [Google Scholar]
32. Emmett L, van Leeuwen PJ, Nandurkar R, et al. Treatment outcomes from 68 Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET. J Nucl Med 2017; 58:1972–1976 [Crossref] [Medline] [Google Scholar]
33. Han S, Woo S, Kim YJ, Suh CH. Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2018; 74:179–190 [Crossref] [Medline] [Google Scholar]
34. Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68 Ga-PSMA-positron emission tomography/computerized tomography. Prostate 2015; 75:1934–1940 [Crossref] [Medline] [Google Scholar]
35. Soldatov A, von Klot CAJ, Walacides D, et al. Patterns of progression after 68 Ga-PSMA-ligand PET/CT-guided radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 2019; 103:95–104 [Crossref] [Medline] [Google Scholar]
36. Lengana T, Lawal IO, Boshomane TG, et al. 68 Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer 2018; 16:392–401 [Crossref] [Medline] [Google Scholar]
37. Zacho HD, Nielsen JB, Afshar-Oromieh A, et al. Prospective comparison of 68 Ga-PSMA PET/CT, 18 F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45:1884–1897 [Crossref] [Medline] [Google Scholar]
38. Uprimny C, Svirydenka A, Fritz J, et al. Comparison of [68 Ga]Ga-PSMA-11 PET/CT with [18 F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Eur J Nucl Med Mol Imaging 2018; 45:1873–1883 [Crossref] [Medline] [Google Scholar]
39. Hope TA, Truillet C, Ehman EC, et al. 68 Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med 2017; 58:81–84 [Crossref] [Medline] [Google Scholar]
40. Afshar-Oromieh A, Debus N, Uhrig M, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45:2045–2054 [Crossref] [Medline] [Google Scholar]
41. Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA. Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study. Nucl Med Mol Imaging 2018; 52:420–429 [Crossref] [Medline] [Google Scholar]
42. Seitz AK, Rauscher I, Haller B, et al. Preliminary results on response assessment using 68 Ga-HBED-CC-PSMA PET/CT in patients with meta-static prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging 2018; 45:602–612 [Crossref] [Medline] [Google Scholar]
43. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177 Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017; 58:85–90 [Crossref] [Medline] [Google Scholar]
44. Hofman MS, Violet J, Hicks RJ, et al. [177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19:825–833 [Crossref] [Medline] [Google Scholar]
45. Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016; 43:795–796 [Crossref] [Medline] [Google Scholar]
46. Osman MM, Iravani A, Hicks RJ, Hofman MS. Detection of synchronous primary malignancies with 68 Ga-labeled prostate-specific membrane antigen PET/CT in patients with prostate cancer: frequency in 764 patients. J Nucl Med 2017; 58:1938–1942 [Crossref] [Medline] [Google Scholar]
47. Jochumsen MR, Gormsen LC, Nielsen GL. 68 Ga-PSMA avid primary adenocarcinoma of the lung with complementary low 18 F-FDG uptake. Clin Nucl Med 2018; 43:117–119 [Crossref] [Medline] [Google Scholar]
48. Huang HL, Zhen Loh TJ, Hoe Chow PK. A case of well-differentiated hepatocellular carcinoma identified on gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography. World J Nucl Med 2018; 17:102–105 [Medline] [Google Scholar]
49. Sasikumar A, Joy A, Pillai MRA, et al. Diagnostic value of 68 Ga PSMA-11 PET/CT imaging of brain tumors: preliminary analysis. Clin Nucl Med 2017; 42:e41–e48 [Crossref] [Medline] [Google Scholar]
50. Sasikumar A, Kashyap R, Joy A, et al. Utility of 68 Ga-PSMA-11 PET/CT in imaging of glioma: a pilot study. Clin Nucl Med 2018; 43:e304–e309 [Crossref] [Medline] [Google Scholar]
51. Arora S, Damle NA, Aggarwal S, et al. Prostate-specific membrane antigen expression in adreno-cortical carcinoma on 68 Ga-prostate-specific membrane antigen PET/CT. Clin Nucl Med 2018; 43:449–451. [Medline] [Google Scholar]
52. Stoykow C, Huber-Schumacher S, Almanasreh N, Jilg C, Ruf J. Strong PSMA radioligand up-take by rectal carcinoma: who put the “S” in PSMA? Clin Nucl Med 2017; 42:225–226 [Crossref] [Medline] [Google Scholar]
53. Hangaard L, Jochumsen MR, Vendelbo MH, Bouchelouche K. Metastases from colorectal cancer avid on 68 Ga-PSMA PET/CT. Clin Nucl Med 2017; 42:532–533 [Crossref] [Medline] [Google Scholar]
54. Huang Y-TT, Fong W, Thomas P. Rectal carcinoma on 68 Ga-PSMA PET/CT. Clin Nucl Med 2016; 41:e167–e168 [Crossref] [Medline] [Google Scholar]
55. Noto B, Weckesser M, Buerke B, Pixberg M, Avramovic N. Gastrointestinal stromal tumor showing intense tracer uptake on PSMA PET/CT. Clin Nucl Med 2017; 42:200–202 [Crossref] [Medline] [Google Scholar]
56. Laurens ST, Witjes F, Janssen M, Flucke U, Gottardt M. 68 Ga-prostate-specific membrane antigen uptake in gastrointestinal stromal tumor. Clin Nucl Med 2018; 43:60–61 [Crossref] [Medline] [Google Scholar]
57. Sasikumar A, Joy A, Pillai M, S B, Sr S. 68Ga-PSMA uptake in an incidentally detected gastrointestinal stromal tumor in a case of suspected carcinoma prostate. Clin Nucl Med 2017; 42:e447–e448 [Crossref] [Medline] [Google Scholar]
58. Kesler M, Levine C, Hershkovitz D, et al. 68 Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med 2018 Jul 12 [Epub ahead of print] [Medline] [Google Scholar]
59. Demirkol MO, Kiremit MC, Acar O, Sag AA, Kapran Y. False-positive pancreatic uptake detected on 68 Ga-PSMA PET/CT: a priority changing incidental finding while assessing the need for a prostate biopsy. Clin Nucl Med 2017; 42:e475–e477 [Crossref] [Medline] [Google Scholar]
60. Parihar AS, Vadi SK, Mittal BR, Kumar R, Bal A, Singh SK. 68 Ga-PSMA-HBED-CC-avid synchronous urinary bladder paraganglioma in a patient with metastatic prostate carcinoma. Clin Nucl Med 2018; 43:e329–e330 [Crossref] [Medline] [Google Scholar]
61. Parida GK, Tripathy S, Datta Gupta S, et al. Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18 F-FDG PET/CT and 68 Ga-DOTANOC PET/CT over 68 Ga-PSMA PET/CT. Clin Nucl Med 2018; 43:248–249 [Medline] [Google Scholar]
62. Usmani S, Ahmed N, Marafi F, Rasheed R, Amanguno HG, Al Kandari F. Molecular imaging in neuroendocrine differentiation of prostate cancer: 68 Ga-PSMA versus 68 Ga-DOTA NOC PET-CT. Clin Nucl Med 2017; 42:410–413 [Crossref] [Medline] [Google Scholar]
63. Chen S, Cheung SK, Wong K-N, Wong KK, Ho C-L. 68 Ga-DOTATOC and 68 Ga-PSMA PET/CT unmasked a case of prostate cancer with neuroendocrine differentiation. Clin Nucl Med 2016; 41:959–960 [Crossref] [Medline] [Google Scholar]
64. Singh D, Kumar R, Mittal BR, Singh H, Bhattacharya A. 68 Ga-labeled prostate-specific membrane antigen uptake in pheochromocytoma: an incidental finding in PET/CT scan. Clin Nucl Med 2018; 43:688–690 [Crossref] [Medline] [Google Scholar]
65. Evangelista L, Basso U, Maruzzo M, Novara G. The role of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for the evaluation of renal cancer. Eur Urol Focus 2018 Aug 14 [Epub ahead of print] [Crossref] [Medline] [Google Scholar]
66. Rhee H, Ng KL, Tse BW-C, et al. Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology 2016; 48:613–616 [Crossref] [Medline] [Google Scholar]
67. Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a 68 Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging 2017; 44:102–107 [Crossref] [Medline] [Google Scholar]
68. Demirci E, Ocak M, Kabasakal L, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2014; 41:1461–1462 [Crossref] [Medline] [Google Scholar]
69. Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68 Ga prostate specific membrane antigen positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol 2017; 61:372–378 [Crossref] [Medline] [Google Scholar]
70. Einspieler I, Tauber R, Maurer T, Schwaiger M, Eiber M. 68 Ga prostate-specific membrane antigen uptake in renal cell cancer lymph node metastases. Clin Nucl Med 2016; 41:e261–e262 [Crossref] [Medline] [Google Scholar]
71. Gupta M, Choudhury PS, Gupta G, Gandhi J. Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy. Indian J Nucl Med 2016; 31:222–224 [Crossref] [Medline] [Google Scholar]
72. Merrild EH, Baerentzen S, Bouchelouche K, Buus S. Vertebral myeloma mimicking prostatic carcinoma metastasis in 68 Ga-PSMA PET/CT. Clin Nucl Med 2017; 42:790–792 [Crossref] [Medline] [Google Scholar]
73. Rauscher I, Maurer T, Steiger K, Schwaiger M, Eiber M. Image of the month: multifocal 68 Ga prostate-specific membrane antigen ligand up-take in the skeleton in a man with both prostate cancer and multiple myeloma. Clin Nucl Med 2017; 42:547–548 [Crossref] [Medline] [Google Scholar]
74. Sasikumar A, Joy A, Pillai MRA, Nanabala R, Thomas B. 68 Ga-PSMA PET/CT imaging in multiple myeloma. Clin Nucl Med 2017; 42:e126–e127 [Crossref] [Medline] [Google Scholar]
75. Sasikumar A, Joy A, Pillai MRA, Alex TM, Narayanan G. 68 Ga-PSMA PET/CT in osteosarcoma in fibrous dysplasia. Clin Nucl Med 2017; 42:446–447 [Crossref] [Medline] [Google Scholar]
76. De Coster L, Sciot R, Everaerts W, et al. Fibrous dysplasia mimicking bone metastasis on 68 GA PSMA PET/MRI. Eur J Nucl Med Mol Imaging 2017; 44:1607–1608 [Crossref] [Medline] [Google Scholar]
77. Sakthivel P, Prashanth A, Thakar A, Kumar R, Kumar R. Juvenile nasal angiofibroma on 68 Ga-PSMA PET/CT: opening new frontiers. Clin Nucl Med 2019; 44:e118–e119 [Crossref] [Medline] [Google Scholar]
78. Krishnaraju VS, Basher RK, Singh H, Singh SK, Bal A, Mittal BR. Incidental detection of type B2 thymoma on 68 Ga-labeled prostate-specific membrane antigen PET/CT imaging. Clin Nucl Med 2018; 43:356–358 [Medline] [Google Scholar]
79. Farolfi A, Ceci F, Graziani T, et al. Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in a patient with recurrent prostate cancer. Clin Genitourin Cancer 2018; 16:e497–e499 [Crossref] [Medline] [Google Scholar]
80. Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental detection of head and neck squamous cell carcinoma on 68 Ga-PSMA-11 PET/CT. Clin Nucl Med 2017; 42:e218–e220 [Crossref] [Medline] [Google Scholar]
81. Verma P, Malhotra G, Agrawal R, Sonavane S, Meshram V, Asopa RV. Evidence of prostate-specific membrane antigen expression in meta-static differentiated thyroid cancer using 68 Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med 2018; 43:e265–e268 [Crossref] [Medline] [Google Scholar]
82. Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer? Clin Nucl Med 2016; 41:e263–e265 [Crossref] [Medline] [Google Scholar]
83. Sasikumar A, Joy A, Pillai MRA, Oommen KE, Jayakumar R. Rare case of intratracheal metastasis detected on 68 Ga-prostate-specific membrane antigen PET/CT scan in a case of thyroglobulin elevated negative iodine scan syndrome. Clin Nucl Med 2018; 43:282–283 [Medline] [Google Scholar]
84. Sager S, Vatankulu B, Uslu L, Sönmezoglu K. Incidental detection of follicular thyroid carcinoma in 68 Ga-PSMA PET/CT imaging. J Nucl Med Technol 2016; 44:199–200 [Crossref] [Medline] [Google Scholar]
85. Damle NA, Bal C, Singh TP, et al. Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers. Eur J Nucl Med Mol Imaging 2018; 45:667–668 [Crossref] [Medline] [Google Scholar]
86. Jena A, Zaidi S, Kashyap V, Jha A, Taneja S. PSMA expression in multinodular thyroid neoplasm on simultaneous Ga-68-PSMA PET/MRI. Indian J Nucl Med 2017; 32:159–161 [Crossref] [Medline] [Google Scholar]
87. Derlin T, Kreipe H-H, Schumacher U, Soudah B. PSMA expression in tumor neovasculature endothelial cells of follicular thyroid adenoma as identified by molecular imaging using 68 Ga-PSMA ligand PET/CT. Clin Nucl Med 2017; 42:e173–e174 [Crossref] [Medline] [Google Scholar]
88. Damle NA, Tripathi M, Chakraborty PS, et al. Unusual uptake of prostate specific tracer 68 Ga-PSMA-HBED-CC in a benign thyroid nodule. Nucl Med Mol Imaging 2016; 50:344–347 [Crossref] [Medline] [Google Scholar]
89. Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E. Follicular thyroid adenoma showing avid uptake on 68 Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016; 41:331–332 [Crossref] [Medline] [Google Scholar]
90. Patro KC, Palla M, Kashyap R. Unusual case of metastatic intracranial hemangiopericytoma and emphasis on role of 68 Ga-PSMA PET in imaging. Clin Nucl Med 2018; 43:e331–e333 [Crossref] [Medline] [Google Scholar]
91. Malik D, Mittal BR, Kumar R, Singh H, Bhattacharya A, Singh SK. Incidental detection of tracer avidity in liposarcoma on 68 Ga-labeled prostate-specific membrane antigen PET/CT. Clin Nucl Med 2018; 43:e334–e335 [Crossref] [Medline] [Google Scholar]
92. Snow HA, Hofman MS, Mitchell CA, Gyorki DE, Smith MJF. Incidental metastatic melanoma identified on 68 Ga-prostate-specific membrane antigen PET/CT for metastatic prostate cancer. Clin Nucl Med 2018; 43:509–511 [Crossref] [Medline] [Google Scholar]
93. Anconina R, Hod N, Levin D, Ezroh Kazap D, Lantsberg S. Incidental detection of metastatic malignant melanoma on 68 Ga-prostate-specific membrane antigen PET/CT imaging: correlative imaging with FDG PET/CT and review of the literature. Clin Nucl Med 2018; 43:204–206 [Crossref] [Medline] [Google Scholar]
94. Vamadevan S, Le K, Bui C, Mansberg R. Prostate-specific membrane antigen uptake in small cleaved B-cell follicular non-Hodgkin lymphoma. Clin Nucl Med 2016; 41:980–981 [Crossref] [Medline] [Google Scholar]
95. Kanthan GL, Coyle L, Kneebone A, Schembri GP, Hsiao E. Follicular lymphoma showing avid uptake on 68 Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016; 41:500–501 [Crossref] [Medline] [Google Scholar]
96. Sathekge M, Lengana T, Modiselle M, et al. 68 Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging 2017; 44:689–694 [Crossref] [Medline] [Google Scholar]
97. Sathekge M, Modiselle M, Vorster M, et al. 68 Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging 2015; 42:1482–1483 [Crossref] [Medline] [Google Scholar]
98. Chia JY, Loi HY, Khor LK, Joe Lee KC, Seow YH. Primary lung adenocarcinoma with 68 gallium prostate-specific membrane antigen-PET/CT scan avidity in a patient on surveillance after prostatectomy. Clin Genitourin Cancer 2018; 16:e525–e527 [Crossref] [Medline] [Google Scholar]
99. Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68 Ga prostate-specific membrane antigen activity in metastatic non-small cell lung cancer. Clin Nucl Med 2016; 41:414–416 [Crossref] [Medline] [Google Scholar]
100. Backhaus P, Noto B, Avramovic N, et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging 2018; 45:860–877 [Crossref] [Medline] [Google Scholar]
101. Jochumsen MR, Bouchelouche K. Intense 68 Ga-PSMA uptake in diverticulum of the sigmoid colon. Clin Nucl Med 2018; 43:110–111 [Crossref] [Medline] [Google Scholar]
102. Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK. 68 Ga-labeled PSMA uptake in nonprostatic malignancies: has the time come to remove “PS” From PSMA? Clin Nucl Med 2018; 43:529–532 [Crossref] [Medline] [Google Scholar]
103. Pfob CH, Karimov I, Jesinghaus M, et al. Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma. Eur J Nucl Med Mol Imaging 2018 Dec 19 [Epub ahead of print] [Google Scholar]
104. Lütje S, Gomez B, Cohnen J, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68 Ga-HBED-CC-PSMA PET/CT. Clin Nucl Med 2017; 42:20–25 [Crossref] [Medline] [Google Scholar]
105. Dekker I, van der Leest M, van Rijk MC, Gerritsen WR, Arens AIJ. 68 Ga-PSMA uptake in angiolipoma. Clin Nucl Med 2018; 43:757–758 [Medline] [Google Scholar]
106. Bilgin R, Ergül N, Çermik TF. Incidental meningioma mimicking metastasis of prostate adeno-carcinoma in 68 Ga-labeled PSMA ligand PET/CT. Clin Nucl Med 2016; 41:956–958 [Crossref] [Medline] [Google Scholar]
107. Vadi SK, Kumar R, Singh H, Singh SK, Mittal BR. 68 Ga-prostate-specific membrane antigen expression in neurocysticercosis lesions in a patient with prostate carcinoma. Clin Nucl Med 2018; 43:e122–e124 [Medline] [Google Scholar]
108. Stephens M, Kim DI, Shepherd B, Gustafson S, Thomas P. Intense uptake in amyloidosis of the seminal vesicles on 68 Ga-PSMA PET mimicking locally advanced prostate cancer. Clin Nucl Med 2017; 42:147–148 [Crossref] [Medline] [Google Scholar]
109. Pyka T, Weirich G, Einspieler I, et al. 68 Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med 2016; 57:367–371 [Crossref] [Medline] [Google Scholar]
110. Daglioz Gorur G, Hekimsoy T, Isgoren S. Re: false positive uptake in bilateral gynecomastia on 68 Ga-PSMA PET/CT scan. Clin Nucl Med 2018; 43:785 [Medline] [Google Scholar]
111. Pedersen MA, Bouchelouche K, Vendelbo MH. 68 Ga-PSMA uptake in middle lobe syndrome. Clin Nucl Med 2018; 43:e376–e377 [Medline] [Google Scholar]
112. Huang HL, Dharmawan AR, Tan CJ, Thang SP. A rare case of thymoma first detected on gallium-68 PSMA PET/CT. Eur J Nucl Med Mol Imaging 2017; 44:2148–2149 [Crossref] [Medline] [Google Scholar]
113. Strele-Trieb P, Dunzinger A, Sonnberger M, Wolfsgruber J, Pichler R. Uptake of 68 Ga-prostate-specific membrane antigen PET in adrenal gland: a potential pitfall. Clin Nucl Med 2018; 43:50–51 [Crossref] [Medline] [Google Scholar]
114. Law WP, Fiumara F, Fong W, Miles KA. Gallium-68 PSMA uptake in adrenal adenoma. J Med Imaging Radiat Oncol 2016; 60:514–517 [Crossref] [Medline] [Google Scholar]
115. Jochumsen MR, Dias AH, Bouchelouche K. Benign traumatic rib fracture: a potential pitfall on 68 Ga-prostate-specific membrane antigen PET/CT for prostate cancer. Clin Nucl Med 2018; 43:38–40 [Crossref] [Medline] [Google Scholar]
116. Vamadevan S, Le K, Bui C, Mansberg R. Incidental PSMA uptake in an undisplaced fracture of a vertebral body. Clin Nucl Med 2017; 42:465–466 [Crossref] [Medline] [Google Scholar]
117. Hoberück S, Michler E, Kaiser D, Röhnert A, Zöphel K, Kotzerke J. Prostate-specific membrane antigen expression in distal radius fracture. Clin Nucl Med 2018; 43:611–613 [Crossref] [Medline] [Google Scholar]
118. Gykiere P, Goethals L, Everaert H. Healing sacral fracture masquerading as metastatic bone disease on a 68 Ga-PSMA PET/CT. Clin Nucl Med 2016; 41:e346–e347 [Crossref] [Medline] [Google Scholar]
119. Castello A, Lopci E. Incidental identification of osteoid osteoma by 68 Ga-PSMA PET/CT. Eur J Nucl Med Mol Imaging 2018; 45:509–510 [Crossref] [Medline] [Google Scholar]
120. Shetty D, Patel D, Le K, Bui C, Mansberg R. Pitfalls in gallium-68 PSMA PET/CT interpretation: a pictorial review. Tomography 2018; 4:182–193 [Crossref] [Medline] [Google Scholar]
121. Froehner M, Toma M, Zöphel K, Novotny V, Laniado M, Wirth MP. PSMA-PET/CT-positive Paget disease in a patient with newly diagnosed prostate cancer: imaging and bone biopsy findings. Case Rep Urol 2017; 2017:1654231 [Medline] [Google Scholar]
122. Bourgeois S, Gykiere P, Goethals L, Everaert H, De Geeter FW. Aspecific uptake of 68GA-PSMA in Paget disease of the bone. Clin Nucl Med 2016; 41:877–878 [Crossref] [Medline] [Google Scholar]
123. Artigas C, Alexiou J, Garcia C, et al. Paget bone disease demonstrated on (68) Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging 2016; 43:195–196 [Crossref] [Medline] [Google Scholar]
124. Sahoo MK, Ahlawat K, Yadav R, Gajendra S. Schmorl's node: confusion still persists in (68) Ga-prostate-specific membrane antigen ligand PET/CT. Clin Nucl Med 2018; 43:679–681 [Crossref] [Medline] [Google Scholar]
125. Probst S, Bladou F, Abikhzer G. Extraosseous extension of aggressive vertebral hemangioma as a potential pitfall on 68 Ga-PSMA PET/CT. Clin Nucl Med 2017; 42:624–625 [Medline] [Google Scholar]
126. Zacho HD, Nielsen JB, Dettmann K, Hjulskov SH, Petersen LJ. 68 Ga-PSMA PET/CT uptake in intramuscular myxoma imitates prostate cancer metastasis. Clin Nucl Med 2017; 42:487–488 [Crossref] [Medline] [Google Scholar]
127. Oh G, Miles K. Subacute cerebellar infarction with uptake on 68 Ga–prostate-specific membrane antigen PET/CT. Clin Nucl Med 2018; 43:134–135 [Crossref] [Medline] [Google Scholar]
128. Chan M, Hsiao E. Subacute cortical infarct showing uptake on 68 Ga-PSMA PET/CT. Clin Nucl Med 2017; 42:110–111 [Crossref] [Medline] [Google Scholar]
129. Dias AH, Bouchelouche K. Prostate-specific membrane antigen PET/CT incidental finding of a schwannoma. Clin Nucl Med 2018; 43:267–268 [Medline] [Google Scholar]
130. Rischpler C, Maurer T, Schwaiger M, Eiber M. Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging 2016; 43:193–194 [Crossref] [Medline] [Google Scholar]
131. Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Im-aging 2017; 44:2117–2136 [Crossref] [Medline] [Google Scholar]
132. Dias AH, Holm Vendelbo M, Bouchelouche K. Prostate-specific membrane antigen PET/CT: up-take in lymph nodes with active sarcoidosis. Clin Nucl Med 2017; 42:e175–e176 [Crossref] [Medline] [Google Scholar]
133. Hermann RM, Djannatian M, Czech N, Nitsche M. Prostate-specific membrane antigen PET/CT: false-positive results due to sarcoidosis? Case Rep Oncol 2016; 9:457–463 [Crossref] [Medline] [Google Scholar]
134. Kobe C, Maintz D, Fischer T, Drzezga A, Chang D-H. Prostate-specific membrane antigen PET/CT in splenic sarcoidosis. Clin Nucl Med 2015; 40:897–898 [Crossref] [Medline] [Google Scholar]
135. Elri T, Aras M, Salihoglu YS, Erdemir RU, Cabuk M. A potential pitfall in the use of 68 Ga-PSMA PET/CT: anthracosis. Rev Esp Med Nucl Imagen Mol 2017; 36:65–66 [Medline] [Google Scholar]
136. McGuiness M, Sounness B. 68 Ga-PSMA-ligand PET/CT uptake in anthracosilicosis. Clin Nucl Med 2017; 42:e431–e432 [Crossref] [Medline] [Google Scholar]
137. Klein Nulent TJ, van Es RJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma: a preliminary analysis. Eur J Nucl Med Mol Imaging 2017; 44:1614–1621 [Crossref] [Medline] [Google Scholar]
Address correspondence to S. Osmany (saabry@yahoo.com).
Read More: https://www.ajronline.org/doi/abs/10.2214/AJR.19.21084
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου